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Abstract 
 
This study investigates inequality and inequity in pharmaceutical utilization in 
Ontario. First, I compare inequality and inequity in drug use between senior and non-senior 
population in Ontario at each of three points in time. During this time period, all seniors in 
Ontario have been universally covered by the publicly financed OBD program. This is not 
the case for the non-senior population. Second, I examine the changes in inequality and 
inequity for each population group at each of the three time points: 1990, 1996/97 and 
2000/01.  During this period, cost-sharing and other changes were introduced into the ODB, 
which allows us to identify the influence on equity of changes on drug coverage policies.  
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1. Introduction 
 
 Most developed countries regard equity in health care access as a crucial element of 
health system performance. Canada has achieved universal, first-dollar coverage1 for its 
population for a comprehensive package of medically necessary physician and hospital 
services. However, even under public and universal coverage, the patterns of equity in the 
utilization of these services vary. For GP and hospital services, most studies (Eyles et al. 
1995; Newbold et al. 1995; Van Doorslaer et al. 2002; Van Doorslaer et al. 2004; Van 
Doorslaer et al. 1992) have found little or no evidence of inequity in access; variations in 
utilization occur mainly according to need.  For specialist services, however, a number of 
studies (Alter et al. 1999; Van Doorslaer et al. 2002; Van Doorslaer et al. 2004) have found 
evidence of inequity in access; variations in utilization reflect a strong influence of non-
need factors such as income and education. 
Pharmaceutical insurance in out-of-hospital settings is neither universal nor 
comprehensive within the public health insurance system in Canada. Currently, coverage 
for prescription drugs in Canada is offered through a mixture of public and private 
insurance plans. In 2000, 53% of Canadians were covered by public drug plans, 58% of 
Canadians were covered by private drug plans, 13% of Canadians were covered by both 
private and public drug plans, and 2% of Canadians didn’t have any form of drug coverage 
(Fraser Group and Tristat Resources 2002).  
The Canadian Institute for Health Information (2005a) estimates that expenditure on 
prescribed drugs accounts for 82.5% of total drug expenditure in Canada in 2004. The non-
prescribed drugs are mainly paid by individual out-of-pocket expenditure. For the 
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prescribed drugs, the expenditures are shared by public drug insurance plans, private drug 
insurance plans and individual out-of-pocket payment. In 2002, the public share of 
spending on prescription drugs was 46.4%. The remaining proportions were paid by private 
insurers (33.8%) and patients’ out-of-pocket money (19.8%).   
Variation in drug coverage among the Canadian population may lead to inequity in 
the access to needed medications. Although a few studies (Alan et al. 2002; Alan et al. 
2005) have considered the distributional effects of public drug subsidies, no study has 
evaluated overall equity in drug utilization. However, we need to investigate equity in drug 
utilization because prescribed drug utilization has become a more and more important 
component of health care services worldwide. In Canada, between 1975 and 2004, per 
capita prescribed drug expenditure in Canada has risen from $119 to $562 2 ; and 
expenditure on prescribed drugs as a proportion of total health expenditure has increased 
from 6.3% to 13.8% (Canadian Institute for Health Information 2005b). Prescribed drug 
expenditure has increased at a more rapid rate than any other health care expenditure. 
Moreover, as drugs are used increasingly as the therapy of choice for many conditions, their 
potential applications to improve health are expanding rapidly. Because equity in health 
care access is the goal of most health care systems, when the importance of drug use among 
health care services goes up, equity in drug utilization is increasingly important for overall 
system performance.   
This study investigates income-related equality and equity in pharmaceutical 
utilization in Ontario and the influence of public drug insurance on this equality and equity. 
The fundamental difference between inequity and inequality resides in the fact that inequity 
represents inequality that is considered and qualified as unjust and avoidable. As a result, 
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measuring inequality in pharmaceutical utilization represents the first step towards the 
identification of inequity in pharmaceutical utilization. This is a two-dimensional study, 
both cross-sectional and over time, and also across population groups. First, I compare 
income-related equality and equity in drug use between the senior population and non-
senior population in Ontario at each of three points in time. All seniors in Ontario are 
universally covered by the publicly financed Ontario Drug Benefit (ODB) program. This is 
not the case for the non-senior population. Therefore, this difference in coverage provides 
an opportunity to examine the impact of universal drug coverage on income-related 
equality and equity in drug utilization. Second, I examine the changes in income-related 
equality and equity for each population group at each of the three time points: 1990, 
1996/97 and 2000/01.  During this period, cost-sharing and other changes were introduced 
into the ODB, which allow us to identify the influence on income-related equality and 
equity of changes in drug coverage policies. 
The analysis proceeds as follows. First, at each time point, I identify whether there 
exists income-related inequality in observed drug utilization for each population group.  
Inequality here refers to the degree to which the individuals in an income distribution have 
shares of drug utilization that are unequal in quantity. Secondly, I measure the income-
related inequity in drug use. The goal of most health care systems is equity rather than 
equality. Equity here refers to horizontal equity, namely access to drugs by all people on 
the basis of need. When the term “access” is used in most empirical studies, it is usually 
defined as “receipt of treatment”. However, access to treatment and receipt of treatment 
may not be the same thing. The former refers to the opportunities open to people, while the 
latter is related to the realization of the opportunities. If an individual does not realize the 
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opportunities at his or her own will, inequity in access may not be a problem. Since it is 
difficult to find measures on opportunities open to people in the datasets, I follow most 
empirical studies by measuring access as receipt of treatment in this analysis. Therefore, for 
the system being equitable, people with equal need should utilize the same amount of drugs 
regardless of their income or social economic status. Thirdly, I decompose the inequality 
into its causes. The decomposition sheds light on the causes of inequity and can inform 
efforts by policy makers to improve equity in drug utilization. Finally, I compare income-
related inequality and inequity of drug use between population groups and time points. 
In the next section, I briefly introduce drug coverage in Ontario. The third section 
describes the data and methods that I am going to use. The fourth section presents my 
results. In the last section, I will draw my conclusions. 
 
2. Drug Coverage in Ontario 
Coverage for prescription drugs in Ontario is offered through a mixture of public 
and private insurance plans. In 2000, 62% of the residents of Ontario were covered by 
various private drug plans (Fraser Group and Tristat Resources 2002). It is difficult to 
obtain data on the percentage of Ontarians who were covered by private drug plans in 1990 
and 1996/97. However, according to the Canadian Institute for Health Information (2005b), 
the share of private insurers on prescription drug expenditure in Canada was constantly in 
the range of 30.2% to 33.8% from 1988 to 2002. Therefore, we can believe that there are no 
significant changes in the status of private drug coverage in our examining period.  
Currently, there are three publicly financed provincial drug insurance programs in 
operation, administered by the Drug Programs Branch of the Ministry of Health and Long-
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Term Care: the Ontario Drug Benefit (ODB), the Trillium Drug Program (TDP), and the 
Special Drug Program (SDP).  
The target populations of the Ontario Drug Benefit (ODB) program are seniors, 
residents of long-term care facilities and homes for special service care, and social 
assistance recipients. All seniors were universally and fully covered (with no co-payments 
required) by this program from August 1975 to July 14, 1996. From July 15, 1996, single 
seniors who have an annual income of $16,018 or more, and seniors in couples with a 
combined annual income of $24,175 or more pay a $100 annual deductible per senior. After 
paying the deductible, they then pay up to $6.11 toward the dispensing fee for each 
prescription. All the other ODB eligible people may be asked to pay up to $2 for each 
prescription.  
 The Trillium Drug Program (TDP) is available to all residents of Ontario with valid 
Ontario Health Insurance (OHIP) who are not eligible for the ODB program. Individuals or 
families can apply to the Trillium Drug Program if private insurance does not cover 100% 
of their prescription drug costs. The program has a deductible that is based on income and 
family size. The deductible is roughly 4% of total household income. The TDP is provided 
as a last resort for those have a high level of out-of-pocket drug expenditure. It provides a 
protective cap for Ontario residents on drug expenses. The TDP was established in April 
1995. After its establishment, the number of TDP applications has grown rapidly over time. 
From 1996 to 2001, the number of TDP applications increased from 18,172 to 59,599 
(Ontario Ministry of Health and Long Term Care 2005). 
 The Special Drugs Program (SDP) covers the full cost of certain out-patient drugs 
used in the treatment of specific conditions. For example the program covers many drugs 
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for the treatment of cystic fibrosis. To qualify, an individual must have one of the diseases 
or conditions covered and meet established criteria. Under the program there are no 
deductibles or co-payments. Eligible people do not have to pay for these treatments. The 
total public SDP cost increased from $82.6 million in 1996/97 to $107.3 million in 
2000/013 (Ontario Ministry of Health and Long Term Care 2005). 
At the first time point (1990) of my study, all seniors in Ontario were universally 
and fully covered by the ODB program. Around 60% of non-seniors were protected by 
various private drug insurances, and a small proportion of non-seniors who received social 
assistance were also covered by the ODB.4  At the last two time points of my study, 
1996/97 and 2000/01, all seniors in Ontario were still universally covered by the ODB, but 
they had to pay a deductible and some co-payments; for the non-seniors, there were two 
new public financed drug insurance plans: TDP and SDP.  
Difference on drug insurance coverage between seniors and non-seniors and the 
over time policy changes may have the following influences on equality and equity in drug 
utilization: 
• Equality and equity in drug utilization among seniors may be more pro-poor than 
that among non-seniors. 
• The imposition of deductibles and co-payments for seniors in the mid of 1990s 
might have a negative influence (pro-rich) on equality and equity in drug utilization. 
• The implementation of TDP and SDP may have a positive influence (pro-poor) on 
equality and equity in drug utilization among non-seniors. 
In the following analysis, I will examine the above hypotheses.  
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 3. Data, Variables and Methods  
 To analyze equality and equity in drug utilization, we need individual level 
information on drug use, income, and other variables that may affect drug use, e.g., gender, 
age, health status, recent illness and injury, education, immigration status, and additional 
medical insurance information. 
 
3.1 Data 
 The data for the three time points in this study come from 1990 Ontario Health 
Survey (OHS), the public use file of 1996/97 National Population Health Survey (NPHS) 
and the master file of 2000/01 Canadian Community Health Survey (CCHS). 
 
OHS 1990 
The 1990 Ontario Health Survey is a comprehensive health survey of the population 
of Ontario, sampling all 42 public health units that existed at the time. Certain groups such 
as the homeless, aboriginal people on reserves, and those living in institutions were 
excluded. The survey was conducted by face-to-face interview from January 1990 to 
November 1990 (excluding July). 
The OHS asked each subject the following question regarding drug utilization:  
“How many different numbers of prescription drugs have you taken in the last 4 weeks?”  
Responses to this question form the basis for the measure of drug utilization in this analysis. 
The OHS also contains measures of health status, socioeconomic status, household and 
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demographic information, income, medical insurance, etc., which are necessary for this 
analysis.  
The total sample size for the OHS 1990 is 77,663. To make the analyses comparable 
over time, the observations between age 1 and age 11 are excluded. The NPHS 1996/97 and 
CCHS 2000/01 only contain information on drug utilization for people aged 12 and older. 
The sample size for the non-senior population between age 12 and 64 is 53,820; the sample 
size for the senior population aged 65 or over is 8,769. 
 
NPHS 1996/97 
The NPHS 1996/97 is the second cycle of the National Population Health Survey. 
The National Population Health Survey (NPHS) is designed to collect information related 
to the health of the Canadian population. It is composed of three component parts: the 
survey of households; the survey of institutions and the survey of the North. 
The household component includes household residents in all provinces, with the 
principal exclusion of populations on Indian Reserves, Canadian Forces Bases and some 
remote areas in Quebec and Ontario. This analysis employs the public use file of the 
Ontario section from the household survey of the NPHS 1996/97. The household survey of 
the NPHS contains two separate data files: a general micro-data file and a health micro-data 
file. In each household, some limited information was collected from all household 
members (general micro-data file); one person in each household was randomly selected for 
a more in-depth interview (health micro-data file). The health micro-data file contains 
information about drug utilization for people aged 12 and over. Therefore, my analysis is 
based on the health micro-data file. 
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      The NPHS asked each subject 21 questions as whether he or she has taken a 
particular kind of drug in the past month. A derived variable on “number of different drugs 
taken in the past month” can be constructed based on those questions, and is the 
measurement of drug utilization in this analysis. The NPHS also contains measures on 
health status, socioeconomic status, household and demographic information, income, 
medical insurance, etc., which are necessary for this analysis.  
For the NPHS 1996/97 cycle, the Ontario provincial government provided extra 
funds so that a larger sample of dwellings could be selected. The purpose of this buy-in was 
to obtain sufficient sample size to provide reliable cross sectional estimates at sub-
provincial levels. Therefore, the Ontario part of the NPHS 1996/97 is also referred as OHS 
1996/97. The total sample size for the Ontario health micro-data file in the NPHS 1996/97 
cycle is 39,010. The sample size is 7,102 for the senior population, 31,908 for the non-
senior population. 
For Ontario, data collection ran from October 1996 to August 1997, completely 
after the reform of provincial drug plans in July 1996. Before July 15 1996, Ontario 
provided first dollar coverage without any co-payment to its senior citizens. After that, 
income and household size based deductible and dispensing fee were imposed. Similarly, a 
$2 dispensing fee was introduced after July 15 1996 for the non-senior social assistance 
recipients eligible for the provincial drug plan.  
 
CCHS 2000-2001 
The CCHS 2000/01 is the first cycle of the Canadian Community Health Survey, a 
large sample, general population health survey. Information was collected between 
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September 2000 and November 2001, for 136 health regions, covering all provinces and 
territories. The CCHS (Cycle 1.1) collects responses from persons aged 12 or older, living 
in private occupied dwellings. Individuals living on Indian Reserves and on Crown Lands, 
institutional residents, full-time members of the Canadian Armed Forces, and residents of 
certain remote regions are excluded. 
 The CCHS 2000/01 asked each subject 21 questions as to whether this individual 
has taken a particular kind of drug in the past month. The questions are the same as in the 
NPHS 1996/97. A derived variable on “number of different drugs taken in the past month” 
can be constructed based on those questions, and is the measurement of drug utilization in 
this analysis. One limitation is that the questions on drug use are optional in the CCHS 
2000/01. Only regions with a need for data or interest in this topic selected it in the CCHS. 
100% of the respondents in only 29 public health regions (out of 37) answered those 
questions. The other 8 public health regions did not select this topic. 5  Therefore, the 
observations in those 8 public health regions are excluded from this analysis. The number 
of excluded observations is 20.7% of total observations, but it only represents 16.1% of 
Ontario population. The comparison on descriptive statistics of some key characteristics 
related to health care utilization between the included observations and excluded 
observations is presented in Table 1.  The two sets of numbers are very close, which 
suggests no bias in terms of observed characteristics.   In addition, individual respondents 
played no role in the decision of whether or not to answer these questions, so there is no 
individual-level selection process at work.  Hence, although the missing data are 
unfortunate, little reason to believe it introduced serious selection bias. The CCHS 2000/01 
also contains measures of health status, socioeconomic status, household and demographic 
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information, income, etc. A further problem is that the information on additional medical 
insurance is not collected in CCHS 2000/01.  
The total sample size for the analysis based on the CCHS is 31,133. The sample size 
for the senior population is 25,108, and for the non-senior population is 6,025. 
 
3.2. Variables 
 In this analysis, I adopt the methods developed by the ECUITY group in recent 
years (Van Doorslaer et al. 2002; Van Doorslaer et al. 2004; Van Doorslaer et al. 2000; 
Van Doorslaer et al. 1992; Wagstaff and Van Doorslaer 2000a).This method has been 
applied to many countries internationally, and to EU countries in particular on the issues of 
equity in health care utilization. It has been applied at the national level in Canada with 
respect to hospital and MD services. However, it has never been applied to equity in drug 
utilization anywhere. The approach involves four basic steps at each time point for each 
population group: 
1) Calculate the concentration index (CI) to measure the inequality in observed 
drug use. 
2) Use a two-part model to indirectly need-standardize the drug use. 
3) Calculate the horizontal inequity index (HI) to measure the inequity in drug 
use. 
4) Decompose the inequality into its causes. 
The details of the method are discussed in the next sub-section. The variables used in the 
two-part model are discussed below. 
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Dependent Variable 
The 1990 OHS asks each subject “How many different numbers of prescription 
drugs have you taken in the last 4 weeks?”; NPHS health micro-data file and CCHS contain 
21 identical questions about whether the respondent has taken a particular kind of drug in 
the past month. The information is used to create the two dependent variables. The first is a 
dichotomous variable indicating whether a person consumed at least one drug in the last 
month.  The second is the number of drugs used conditional on positive use.  
There are two limitations to these measures of utilization. First, the number of 
different drugs taken in the past month is a crude measurement of drug utilization. It is 
related only to the crude measurement of quantity rather than the quality of drug use. If data 
allowed, a more accurate measurement of drug utilization would give better estimation and 
understanding of this issue. This is a very common issue in most existing studies on the 
issue of equity in health care utilization. The commonly used dependent variables are 
number of physician visits, number of dentist visits, and number of nights of hospital stay, 
etc. Secondly, utilization in the NPHS and CCHS data include both prescribed and non-
prescribed drugs, while the OHS includes only prescribed drugs. This may lead to 
inconsistency of the results. 
 
Independent Variables 
Table 2 lists the independent variables included in the two-part model and briefly 
describes the rationale for their inclusion. The independent variables can be categorized 
into three groups: demographic variables, health status variables and social-economic 
variables. The demographic variables include indicators of age, sex and immigrant status. 
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Usually, there are strong relations between health care utilization and age and sex. Many 
studies (e.g., Deri 2005) have found lower rates of health care utilization among immigrants, 
therefore, an immigrant variable is included in the model. The health status variables 
include self-assessed health status, number of chronic conditions and illness and injury in 
the past two weeks. The social-economic variables include income per household member, 
education level, working status, and additional medical insurance.  Income per household 
member is a critical variable in this analysis; it is created as follows. The OHS 1990 and 
NPHS 1996/97 contain categorical information on total household income (0-$5000, 
$5000-$9999, $10000-$14999, $15000-$19999, $20000-24999, $25000-$29999, $30000-
$39999, $40000-$49999, $50000-$59999, $60000-$79999, $80000+). The CCHS 2000/01 
contains information on best estimate of total household income. All the datasets also 
contain information on number of individuals in the household. Income per household is 
defined as the mid point of the total household income in each category divided by the 
number of household members in that household. Several variables may capture multiple 
influences on drug utilization, such as education and working status, which are also 
discussed in Table 2. The main purpose of the regression model is prediction rather than the 
estimation of a causal relationship. Therefore, it is not a structural model.   
The descriptive statistics of the variables are presented in Table 3 and Table 4. The 
means of most independent variables are relatively constant over time; one exception is the 
income per household member variable, which increased over time. For the non-seniors, 
there are significant increases of the two dependent variables. The average number of drugs 
used increased from 1.023 to 1.836, and the probability of drug use increased from 0.53 to 
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0.805 from 1990 to 2000/01. For the senior population, the number of drugs used and the 
probability of drug use increased slightly over time. 
 
3.3. Method 
Step 1- Concentration Index for Observed Drug Utilization   
 The concentration index quantifies the degree of inequality in a specific health 
variable – in this case number of drugs consumed – across the income distribution. It is 
defined with the reference to the concentration curve. The concentration curve graphs on 
the x-axis the cumulative percentage of the population ranked by income and on the y-axis 
the cumulative percentage of drug consumption.  
If there is no income-related inequality, the concentration curve is the  line. If 
drug consumption is more concentrated among the poor, the concentration curve lies above 
the line of equality. If drug consumption is more concentrated among the rich, the 
concentration curve lies below the line of equality. The concentration index is defined as 
twice the area between the concentration curve and the line of equality (the  line).  If the 
concentration curve is above the  line, indicating that drug consumption is more 
concentrated among the poor, the concentration index takes on a negative value.  If the 
concentration curve is below the  line, indicating that drug consumption is more 
concentrated among the rich, the concentration index takes on a positive value. The 
concentration index ranges from -1 to 1, -1 means that the poorest person gets all the drugs 
consumed while 1 means that the richest person gets all the drugs consumed, and 0 means 
that drug consumption is the same for every income level.  
045
045
045
045
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The concentration index is calculated by the following formula: 
                                                     
1
2 1
n
i i
i
C y R
nμ == −∑                                        (1) 
where iy  is the drug consumption for individual i, iR  is the rank of income for that 
individual, μ  is the mean of drug consumption, and n is the number of individuals. Both 
the concentration index and its variance can easily be computed using conventional 
statistical software packages. With the standard error, we can test the statistical significance 
of the concentration index and calculate its confidence interval. 
 The concentration index simply measures whether utilization is equal across the 
income groups. The goal of a health care system is equity rather than equality. To assess 
equity, we must assess the extent to which utilization is driven by need. 
 
Step 2-Indirect Need-standardization of Drug Utilization 
At the second step, I use a two-part model to indirectly need-standardize the drug 
utilization. The goal of a health care system is equity rather than equality. A key principle 
of equity for health care systems is allocation according to need. Under this principle, 
horizontal equity requires that persons in equal need of treatment should receive the same 
amount of treatment. Because the concentration index measures only the income-related 
inequality in observed drug utilization, an analysis of equity in drug utilization requires that 
we adjust for underlying need.  
 To adjust for need, I use the indirect need-standardization approach proposed by 
Wagstaff and Van Doorsaler (2000). The measure of drug utilization used in this analysis is 
the number of drugs used in the past month. The need-adjusted drug utilization can be 
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predicted by a two-part model. Jones (2000) provides an overview of the econometric 
methods that have been applied to this kind of count data. For the health data, it is common 
to have a large proportion of zero observation, and “overdispersion”. Overdispersion means 
that the variance of the distribution exceeds the mean. The two-part model accommodates 
the high proportion of zeros.  Under the two-part model in this situation, the first part is a 
logit regression, and the second part is a Negative binomial regression, which deals with the 
“overdispersion”. The dependent variable in the first part of the two-part model is a 
dichotomous variable indicating whether a person consumed at least one drug in the last 
month. The dependent variable in the second part of the two-part model is the number of 
drugs used conditional on positive use.   With the two-part model, not only we could 
measure the equity in the number of drugs used, but also we could measure the equity in the 
probability of drug use. Moreover, several studies (Grootendorst 1995; Jones 2000; Van 
Doorslaer et al. 2000) show that the two-part model is the best choice when the dependent 
variable is a quantitative measure of health care utilization. Therefore, I adopt the two-part 
model approach with appropriate modelling of the count data.  
To measure equity, we need to create a measure in which utilization does not reflect 
the influence of non-need factors; it reflects what utilization would be like if only needs 
drove utilization. Therefore, the need-standardization requires that each variable be 
classified as need-related or non-need-related. In this analysis, the following variables are 
classified as need factors: self-assessed health status, age, number of chronic diseases and 
illness/injury in the past two weeks; and the other variables are classified as non-need 
factors: income, education level, immigrant status, additional insurance status, working 
status. There is no unanimous agreement about what factors should be considered as need 
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factors. Some researchers argue that some factors, such as education and working status, 
should also be considered as need factors. In this case, I simply take the demographic and 
morbidity factors as need factors, because these are much less controversial and are most 
commonly defined as need factors in the equity studies of health care utilization. 
After the estimation of each part, I fix the non-need factors at the sample means, 
and then predict the need-standardized probability and need-standardized number of drugs 
used conditional on positive use based on the need factors. By doing so, we assume the 
population average relationship between need and treatment as the norm of equity. The 
need-standardized expected total number of drug use is equal to the product of need-
standardized probability and need-standardized conditional number. 
 
Step 3-Horizontal Inequity Index 
In the third step, I calculate the horizontal inequity index (HI) for the probability of 
any drug use, conditional number of drugs used and total number of drugs used. 
The horizontal inequity index is equivalent to the concentration index for ISy  (Van 
Doorslaer et al. 2000), where 
IS
i i i
my y y y
∧= − +                                                                                      (2) 
where iy  is the measure of actual drug utilization in the past month, iy
∧
 is the need-adjusted 
measure of drug utilization, and my  is the sample mean of the measure of drug utilization 
in the past month. 
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Step 4-Decomposition of Inequality 
At the last step, I decompose the inequality in observed utilization into its causes. I 
adopt the decomposition method proposed in Wagstaff et al. (2003). In order to use this 
method, the number of drugs used has to be expressed by a linear equation of a set of 
variables that determine drug utilization. In other words, the decomposition has to be based 
on an OLS regression. Van Doorsaler et al. (2004) argue that in most cases, the 
concentration index based on OLS predicted values is close to the true concentration index, 
even if the dependent variable is a count measure. In my case, the concentration index 
based on OLS predicted values is also close to the true concentration index. Therefore, I 
follow the OLS approach. However, because of the nature of count data, the OLS based 
decomposition of inequality is an approximation only.    
In an OLS regression, the number of drugs used can be expressed as 
i k k
k
y x i iα β= + +∑ ε                                                                                   (3)     
where kx  is a set of k determinants of y.  The concentration index is 
1
2 1
n
i i
i
C y R
nμ == ∑ −                                                                                          (4) 
Substitute equation (3) into the above equation, it can be rearranged as 
( )k k k
k
x GCC C εβμ μ= +∑                                                                               (5) 
Where k kxβμ  is the elasticity of drug use with respect to determinant k; is the CI for 
variable k, and 
kC
GCε
μ  is an error term. The estimated inequality in drug use can be 
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expressed as a weighted sum of the inequality in each of its determinants; the weights are 
the drug use elasticities of the determinants. Based on the OLS regression, I decompose the 
concentration index for each population group.  
 
4. Results 
Step 1: Concentration indices for observed drug use 
 Figure 1 and Figure 2 present the average number of drugs used and the average 
number of drugs used for those who have consumed drugs by income quartile. The bar 
graphs can give us a more intuitive impression on the inequality in drug use before I report 
the concentration indices. Generally speaking, people in the lower income quartiles use 
more drugs than people in the higher income quartiles.6 Seniors use more drugs than non-
seniors. And there is a trend of increase in drug utilization over time. 
 The concentration indices measuring the income-related inequality on observed 
drug use are reported in Table 5. The distribution is pro-poor for the senior population at all 
three time points, although not significantly different from zero in 1996/97.  For the non-
senior population, the distribution is pro-poor in 1990 and pro-rich in 1996/97 and 2000/01. 
At all time points, the concentration indices of the senior population are more negative or, 
when positive, smaller (more pro-poor) than those for the non-senior population. From 
1990 to 1996/97, there is an increase of the concentration index for both the senior and non-
senior population. The distribution is less pro-poor over time. This change may result from 
the imposition of deductibles and co-payments of ODB for seniors and from a rapid 
increase of drug utilization for non-seniors. During this period, for the non-senior 
population, the average number of drugs used increased from 1.02 to 1.66, and the 
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probability of drug use increased from 0.53 to 0.78. This increase reflects the changes in 
health technology, whereby more conditions are being treated outside hospital settings. The 
increased drug utilization might be unbalanced in favour of the rich.   From 1996/97 to 
2000/01, the concentration index for the senior population slightly decreases (more pro-
poor), while there is no significant change for the non-senior population. During this period, 
there is no drug policy change for seniors, and the introduction of the Trillium Drug 
Program and the Special Drug Program may mitigate the worsening of the income-related 
inequality among the non-senior population. From 1996 to 2001, the number of TDP 
applications increased from 18,172 to 59,599, and the total SDP cost increased from $82.6 
million to $107.3 million. The aims of these two programs are to help those most in need 
and who have greatest financial constraints. Given the income-related inequality in drug 
utilization is relatively small, the TDP and SDP may have significant influence on the 
distribution of drug utilization across income groups. 
 
Step 2-Indirect Need-standardization of Drug Utilization 
The goal of most health care systems is equity rather than equality. In order to 
measure horizontal inequity, observed drug utilization must be indirectly need-standardized, 
after which we can compute the horizontal inequity index. 
  The first part of the two-part model is a logit model on the probability of drug use. 
The second part of the two-part model is a negative binomial model conditional on positive 
drug use. In view of space considerations, the results of the two-part model are not reported 
here.7 The general patterns are very similar for both parts. Generally speaking, at all three 
time points, for both the senior and non-senior population, there is a strong relationship 
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between drug utilization and need factors (number of chronic diseases, illness/injury in the 
past two weeks, self-assessed health status, sex, age). Drug use is increasing in the number 
of chronic diseases and worse self-assessed health status. The link between drug use and 
non-need factors (education, immigration status, additional drug insurance, working status 
and income) is much weaker. However, compared to the senior population, the link 
between drug use and non-need factors is more salient for non-seniors. The role of 
education, income, and immigrant in drug use are less significant for seniors. For both 
seniors and non-seniors, at the later two time points, the magnitude of the link between 
drug use and need factors is weaker than that in 1990, and the link between drug use and 
non-need factors is stronger. 
After the estimation, I fix the non-need factors at the sample means, and then 
predict the need-standardized probability of drug use, number of drugs used conditional on 
positive use, and total number of drugs used based on the need factors.  
 
Step 3-Horizontal Inequity Index 
In the third step, I calculate the horizontal inequity index (HI) for the probability of 
drug use, drugs used conditional on positive use, and total number of drugs used. The 
results are presented in Table 6.  
There are no evidences of inequity in most aspects of drug use for both seniors and 
non-seniors in 1990. The only exception is that the probability of drug use for non-seniors 
is distributed slightly pro-rich.  However, this pro-rich distribution for the probability of 
drug use is offset by the pro-poor distribution for drugs used conditional on positive use; 
therefore, there is no measured income-related inequity in the total number of drugs used 
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even for non-seniors in 1990. There is evidence of income-related inequity for almost all 
the aspects of drug use for both seniors and non-seniors in 1996/97 and 2000/01. However, 
there are no significant differences in the level of inequity between the later two time points. 
The worsening of equity may result partially from the same reasons that lead to the 
worsening of inequality. I will discuss this in more details at next step. 
At all the three time points, on all aspects of  drug use, the equity performance for 
seniors is better than that of non-seniors. The HI indices for seniors are more negative or, 
when positive, smaller (more pro-poor) than that for non-seniors. Universal drug coverage 
for the senior population might play an important role in drug utilization.  
 
Step 4-Decomposition of inequality 
At each time point, for each population group, I decompose the unadjusted 
inequality (the concentration index) into the separate contributions of the various 
determinants to the total inequality. The summarization of decomposition results are 
presented in Table 7 and Figure 3. 
At all three time points, the overall concentration indices for senior population are 
more negative or smaller than that for non-senior population. There is a more pro-poor 
distribution in drug use among seniors. The decompositions show that the most important 
source of the more pro-poor distribution among seniors is that more seniors suffer from 
poor health, and poor health among the seniors is concentrated among the poor. Compared 
to non-seniors, the need factors, such as higher number of chronic conditions, worse self-
assessed health statuses, and illness/injury in the past two weeks, are more concentrated 
among the poor. Therefore, the concentration indices of these factors for seniors are more 
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negative. Moreover, there is positive relationship between drug use and the need factors. 
Therefore, for seniors, the need factors make larger negative contributions to the total CI’s. 
Among non-seniors, people with relatively higher age usually have worse health status and 
higher income; therefore, the need factors are less concentrated among the poor, and thus 
make less negative contributions to the total CI’s. Part of the gap in the CI’s between 
seniors and non-seniors results from the variables of education, immigration status and 
additional drug insurance. Higher education levels and having additional medical insurance 
are concentrated more among the rich in both the senior and non-senior population. At the 
same time, the positive relationships between drug use and these two variables for non-
seniors are stronger than those for seniors. Therefore, these two variables make positive 
contributions to the gap of inequality in drug use between seniors and non-seniors. 
Immigrants use fewer health care services presumably because of language barriers and 
lack of information about the Canadian health care system, or some other cultural reasons. 
However, immigration status has a different influence on drug use between senior and non-
senior populations. Generally speaking, the negative relationship between immigration 
status and drug utilization is more significant for non-seniors. Moreover, for both seniors 
and non-seniors, immigrants on average have less income, which implies the concentration 
indices for immigration status are negative. Therefore, immigration status makes a positive 
contribution to the gap of inequality in drug use between seniors and non-seniors. Generally 
speaking, without universal coverage, the drug utilization of non-seniors is more influenced 
by non-need factors. 
For both seniors and non-seniors, the most important source for the worsening of 
inequality in drug use over time comes from the income variable. In 1990, there is a 
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negative but statistically insignificant relationship between drug use and income. In 
1996/97 and 2000/01, the relationships between drug use and income become positive and 
statistically significant, and leads to an increase of both inequality and inequity in drug use. 
This change might be related to the introduction of deductibles and co-payments of ODB 
for seniors, and the rapid increase in drug utilization for non-seniors during that period. 
However, because we define equity in drug use in this study as drug use according 
to need, and poor seniors are more in need, therefore, the gap of inequity in drug use (HI)8 
between seniors and non-seniors is not as large as the gap of inequality in drug use (CI) 
between seniors and non-seniors. The horizontal inequity index measures only the 
inequality in drug use that results from non-need factors. The gap in the HI’s between 
seniors and non-seniors is smaller than the gap in the CI’s. 
 
5. Conclusion 
This study analyzes the equality and equity in pharmaceutical utilization in Ontario, 
an issue which has not previously been examined. In 1990, I find no evidence for pro-rich 
inequality and inequity in drug utilization in Ontario for both senior and non-senior 
populations. In 1996/97 and 2000/01, I find evidence for pro-rich inequality and inequity 
for both population groups. At all three time points, the equality and equity performance in 
drug utilization for the senior population dominates that of the non-senior population. 
Universal drug coverage for the senior population might play a role in drug utilization. 
From 1990 to 1996/97, there is a worsening in equality and equity performance for both 
senior and non-senior populations, so that the distribution is less pro-poor over time. This 
result might be partly related to the introduction of deductibles and co-payments for ODB 
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for seniors and to the rapid increase of drug utilization during this period. From 1996/97 to 
2000/01, the equality and equity performance for the senior population slightly decreased, 
while there is no significant change for the non-senior population. The introduction of the 
Trillium Drug Program and the Special Drug Program might mitigate the worsening of 
income-related inequality and inequity among the non-senior population.  
Decomposing the inequality into its causes reveals that poor seniors are more in 
need of drug utilization than poor non-seniors, resulting in more pro-poor distribution of 
drug utilization among seniors. The gap in equity performance between seniors and non-
seniors is not as large as the gap in equality. The gap in equity performance between 
seniors and non-seniors mainly results from the variables of education, immigration status 
and additional drug insurance. Without universal coverage, these variables have greater 
influence on drug utilization among non-seniors. For both seniors and non-seniors, the most 
important cause of worsening equality and equity in drug use over time comes from the 
income variable. This relationship between drug use and income becomes positive and 
statistically significant over time.  
These findings may be confounded by other system changes in the health care 
sector during the study period. The major changes in the physician sector during 1990’s 
would be the introduction and then removal of global physician expenditure caps. The other 
major change would have been hospital restructuring in the late 1990’s. These system 
changes may have influence on drug utilization. However, the impact from these changes 
on the distribution of drug use should be much smaller than the impact on the overall drug 
use. 
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The most important policy implication to be derived from this study is that equity 
performance in drug utilization is closely related to drug coverage policy. Expansion of 
special public drug programs for people highly in need (for example, TDP and SDP), or 
introducing programs for under-utilizing groups such as immigrants (for example, 
programs to reduce language barriers) would improve equity in drug utilization.  
 
Notes 
I would like to thank Jerry Hurley, Tom Crossley, and an anonymous referee for helpful 
comments. I also acknowledge the data support by Statistics Canada RDC at McMaster and 
UWO.  
 
1 First-dollar coverage refers to the health insurance plan without deductibles and co-
payments.  
2 Values are converted in 2004 constant dollars. 
3 Approximately 1.9% out of total drug expenditure in Ontario in 1996 and 1.7% in 2000. 
4 It’s difficult to estimate the size of this group of people. According to Social Development 
Canada (2005), in each year, 5% to 8% Ontarians received social assistance from 1999 to 
2004. Among them, a significant proportion is children and seniors.  
5 The eight excluded PHU’s are: Haliburton-Kawartha-Pine Ridge PHU, Hastings and 
Prince Edward PHU, Brant PHU, Renfrew PHU, KFLA PHU, Ottawa-Carleton PHU, 
Eastern Ontario PHU and Leeds-Grenville-Lanark PHU. 
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6 These seemingly “pro-poor” results are not yet adjusted for need and if the poor have 
greater need, it may nonetheless be the case that the utilization of drugs is not equitable 
with the poor possibly receiving less drugs than would be equitable based on need. 
7 Results of step 2 are available upon request.  
8 By definition, HI index is equal to the sum of contributions of non-need factors to the 
total inequality. 
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Tables 
 
Table-1, Comparison of descriptive statistics between included and excluded 
PHU's, CCHS 2000/01 
 
Excluded PHU's Included PHU's 
 Mean
Std.
dev. Mean 
Std. 
dev. 
Household income 60339 31452 61510 31166 
Education- less than high school  0.270 0.444 0.269 0.444 
Education- high school 0.197 0.397 0.209 0.406 
Education- some post secondary 0.073 0.260 0.077 0.267 
Education- post secondary graduation 0.451 0.498 0.438 0.496 
Female 0.511 0.500 0.509 0.500 
Age 12-14 0.048 0.213 0.044 0.205 
Age 15-19 0.080 0.271 0.081 0.273 
Age 20-24 0.077 0.266 0.081 0.273 
Age 25-29 0.076 0.264 0.080 0.271 
Age 30-34 0.077 0.267 0.088 0.283 
Age 35-39 0.100 0.300 0.110 0.313 
Age 40-44 0.104 0.305 0.103 0.303 
Age 45-49 0.084 0.278 0.093 0.290 
Age 50-54 0.089 0.285 0.077 0.267 
Age 55-59 0.065 0.247 0.057 0.233 
Age 60-64 0.047 0.213 0.046 0.210 
Age 65-69 0.051 0.220 0.043 0.204 
Age 70-74 0.039 0.194 0.039 0.195 
Age 75-79 0.033 0.177 0.030 0.170 
Age 80+ 0.030 0.171 0.027 0.163 
Self-assessed health- excellent 0.254 0.435 0.267 0.442 
Self-assessed health-very good 0.373 0.484 0.365 0.481 
Self-assessed health-good 0.250 0.433 0.246 0.431 
Self-assessed health-fair 0.088 0.283 0.086 0.280 
Self-assessed health-poor 0.034 0.181 0.036 0.186 
Number of family doctor visits in past 
year 3.407 4.778 3.402 4.602 
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Table-2, Independent Variables: Description and Rationale for Inclusion 
 
Variable Description and Rationale Need 
Status 
Demographics  
Age Age of the respondent at the time of interview. Age is defined by a series of 15 categorical variables. 
The reference category is age 12-14. Age is associated with chronic health decline and need for drugs. 
The use of age-specific dummy variable allows maximum flexibility in the age-utilization relationship. 
Y 
Female Male and female have different attitudes and needs for health care services. Sex is indicated by a 
dummy variable, at which female is 1 and male is 0. 
Y 
Immigrant  Indicator of whether the respondent is an immigrant. Immigrant is defined in all the three surveys as 
not born in Canada. Immigrants may experience barriers to drug utilization because of language 
barriers and lack of information about the Canadian health care system. 
N 
Health Status 
Self-
assessed 
health 
status 
Respondent’s self-assessed health status, defined by a series of 5 categorical variables (Excellent, 
Very Good, Good, Fair, And Poor). The reference category is excellent. Self-assessed health status is 
a well-validated general health measure, which is strongly associated with drug utilization. 
Y 
Illness/injury Indicator of whether the respondent has illness or injury (self-reported) in the past two weeks. 
Illness/injury refers to conditions that related to stay in the bed or cutting down on activities, which may 
positively relate to drug utilization. 
Y 
Chronic 
conditions 
Respondent’s self-reported number of chronic conditions. Chronic conditions are strongly associated 
with drug utilization. 
Y 
Socio-economic Status 
Income Income per household member, in thousands. Income may be positively related to the drug utilization. 
Even for the individuals who have drug insurance coverage, most of them are required to pay a 
deductible and/or co-payment for the prescription drugs. 
N 
Education The highest level of education attained by the respondent. Education is defined through a series of N 
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dummy variables (less than high school, high school, some post-secondary, with a degree). Education 
has two opposite potential influences on drug utilization: 1) higher education levels are associated with 
better health which may have negative influence on drug use. 2) higher education levels are 
associated with positive attitude to health care which may have a positive influence on drug use. 
Working 
Status 
Indicator of whether the respondent has held a job (either full time or part time) in the past year. Labour 
force participation has two opposite potential influences on drug utilization: 1) higher time cost and 
better health associated with labour force participation may have negative influence on drug use. 2) 
higher income and better private drug coverage associated with labour force participation may have a 
positive influence on drug use. 
N 
Insurance Indicator of whether the respondent has insurance that covers all or part of the cost of prescription 
medications (Include any private, government or employer-paid plans). It may positively relate to drug 
utilization. This variable is missing in CCHS 2000/01. 
N 
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Table-3, Descriptive statistics, Non-senior Population 
 
 Non-senior Population 
 1990 OHS 1996/97 NPHS 2000/01 CCHS 
 mean 
std 
dev. mean 
std 
dev. mean 
std 
dev. 
Number of drugs used 1.023 1.825 1.660 1.528 1.836 1.630 
Probability of any drug use 0.530 0.757 0.781 0.414 0.805 0.397 
Income  16.770 10.721 20.202 14.536 24.482 20.532  
Female 0.505 0.500 0.521 0.500 0.501 0.500 
Age 15-19 0.106 0.307 0.069 0.254 0.094 0.292 
Age 20-24 0.092 0.290 0.086 0.280 0.094 0.292 
Age 25-29 0.114 0.318 0.106 0.307 0.092 0.290 
Age 30-34 0.122 0.328 0.134 0.340 0.102 0.303 
Age 35-39 0.118 0.323 0.137 0.344 0.128 0.334 
Age 40-44 0.108 0.310 0.109 0.312 0.119 0.324 
Age 45-49 0.087 0.282 0.093 0.290 0.108 0.310 
Age 50-54 0.072 0.259 0.085 0.279 0.090 0.286 
Age 55-59 0.071 0.257 0.072 0.258 0.067 0.250 
Age 60-64 0.066 0.249 0.069 0.253 0.054 0.226 
With 1 chronic condition 0.308 0.462 0.270 0.444 0.276 0.447 
With 2 chronic conditions 0.176 0.381 0.145 0.352 0.161 0.368 
With 3 chronic conditions 0.088 0.283 0.073 0.261 0.082 0.275 
With 4+ chronic conditions 0.075 0.263 0.073 0.260 0.081 0.273 
Illness/injury in past 2 weeks 0.124 0.330 0.119 0.324 0.094 0.292 
Self-assessed health-very good 0.303 0.460 0.403 0.491 0.385 0.487 
Self-assessed health-good 0.214 0.410 0.238 0.426 0.235 0.424 
Self-assessed health-fair 0.053 0.225 0.067 0.249 0.064 0.246 
Self-assessed health-poor 0.013 0.115 0.024 0.153 0.026 0.158 
Education-high school 0.242 0.429 0.181 0.385 0.210 0.408 
Education-some post secondary 0.237 0.425 0.403 0.491 0.349 0.477 
Education-degree 0.109 0.312 0.167 0.373 0.193 0.394 
Immigrant 0.190 0.392 0.189 0.392 0.307 0.461 
Working 0.634 0.482 0.649 0.477 0.745 0.436 
Additional insurance 0.717 0.451 0.680 0.466 --- --- 
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Table-4, Descriptive statistics, senior Population 
 
 Senior Population 
 1990 OHS 1996/97 NPHS 2000/01 CCHS 
 mean 
std 
dev. mean 
std 
dev. mean 
std 
dev. 
Number of drugs used 2.585 2.735 2.310 1.797 2.983 2.036 
Probability of any drug use 0.868 0.810 0.873 0.333 0.922 0.268 
Income  14.93510.387 18.87411.879 21.950 18.008 
Female 0.561 0.496 0.598 0.490 0.561 0.496 
Age 65-69 0.377 0.485 0.313 0.464 0.310 0.462 
Age 70-74 0.259 0.438 0.293 0.455 0.282 0.450 
Age 75-79 0.205 0.404 0.196 0.397 0.213 0.409 
1 chronic conditions 0.229 0.420 0.216 0.412 0.176 0.381 
2 chronic conditions 0.222 0.416 0.212 0.409 0.204 0.403 
3 chronic conditions 0.172 0.378 0.156 0.363 0.183 0.387 
4+ chronic conditions 0.247 0.432 0.245 0.430 0.315 0.465 
Illness/injury in past 2 
weeks 0.153 0.360 0.139 0.346 0.072 0.259 
Self-assessed health-very 
good 0.242 0.429 0.301 0.459 0.241 0.427 
Self-assessed health-good 0.276 0.447 0.333 0.471 0.320 0.466 
Self-assessed health-fair 0.153 0.360 0.173 0.378 0.217 0.412 
Self-assessed health-poor 0.031 0.173 0.059 0.236 0.100 0.300 
Education-high school 0.179 0.384 0.195 0.396 0.199 0.399 
Education-some post 
secondary 0.135 0.342 0.259 0.438 0.249 0.433 
Education-have a 
degree/bachelor, Master, 
PhD  0.053 0.223 0.088 0.284 0.103 0.304 
Immigrant 0.272 0.445 0.275 0.446 0.405 0.491 
Working 0.068 0.252 0.051 0.219 0.094 0.292 
Additional insurance 0.689 0.463 0.600 0.490 --- --- 
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Table 5, Concentration index for observed drug utilization 
 
 
 
1990 OHS 1996-97 NPHS 2000-01 CCHS 
 
Concentration 
Index t-statistics 
Concentration 
Index t-statistics 
Concentration 
Index t-statistics 
 
 
 
 
 
 
 
Senior  
 
 
 
 
 
-0.0657 -5.1328 -0.0094 -1.1899 -0.0229 -2.8272 
Non-
senior 
-0.0210 -2.9577 0.0108 2.5714 0.0118 3.0256 
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Table-6, Horizontal Inequity Index   
 
1990 OHS 1996-97 NPHS 2000-01 CCHS 
 
Horizontal 
Inequity Index t-statistics
Horizontal 
Inequity Index t-statistics
Horizontal 
Inequity Index t-statistics 
Senior -0.0042 -0.7500 0.0019 0.6129 0.0061 3.5882 
Probability of drug use 
Non-
senior 0.0114 2.3750 0.0174 10.8750 0.0187 18.7000 
Senior 
 -0.0200 -1.6667 0.0216 3.7241 0.0178 4.0455 Number of drug use 
conditional on positive 
use 
Non-
senior -0.0466 -1.9256 0.0371 9.5128 0.0321 11.4643 
Senior 
 -0.0112 -1.0667 0.0230 4.8936 0.0208 5.4737 
Total number of drug 
use 
Non-
senior -0.0074 -1.1935 0.0317 11.3214 0.0282 13.4286 
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Table-7, Contribution to the income-related inequality in the number of drug use 
 
Senior Non-senior 
Contribution to Overall CI Contribution to Overall CI 
  
  
  1990 1996/97 2000/01 1990 1996/972000/01 
Income -0.0083 0.0133 0.0026 -0.0023 0.0063 0.0102
Female 0.0003 -0.0005 -0.0015 -0.0030 -0.0040 -0.0051
Age -0.0021 0.0001 0.0005 0.0176 -0.0012 0.0024
Chronic 
Conditions -0.0111 -0.0114 -0.0194 0.0045 -0.0010 0.0003
Illness and injury 
in past 2 weeks -0.0007 -0.0021 -0.0008 0.0002 -0.0020 -0.0018
Self-assessed 
Health Status -0.0257 -0.0168 -0.0216 -0.0187 -0.0137 -0.0136
Education 0.0005 -0.0002 0.0025 -0.0053 0.0062 0.0054
Immigration 
Status 0.0019 0.0010 0.0037 0.0002 0.0028 0.0082
Working Status -0.0020 -0.0008 0.0007 -0.0075 -0.0008 0.0009
Additional 
Insurance -0.0005 0.0029 --- 0.0052 0.0077 --- 
 Error -0.0181 0.0052 0.0105 -0.0119 0.0080 0.0048
CI -0.0657 -0.0094 -0.0229 -0.0210 0.0108 0.0118
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Figures 
 
 
Figure 1. Number of drugs used,by income quartile
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 Figure 2. Number of drugs used for those who have 
consumed drugs, by income quartile
0
0.5
1
1.5
2
2.5
3
3.5
1990
Senior
1990
Non-
senior
1996/97
Senior
1996/97
Non-
senior
2000/01
Senior
2000/01
Non-
senior
N
um
be
r o
f d
ru
g 
us
e
Bottom quartile
2nd quartile
3rd quartile
Top quartile
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41
 
 
Figure 3. Contribution to concentration indices
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